DDL2017 delegates are being targeted by scammers, organizers warn. Callers claiming to be from the DDL organization have been phoning delegates and offering to book accommodations for the conference and then ask for credit card information. Anyone who has provided credit or debit card details to one of these callers should contact their bank … [Read more...] about Scammers targeting DDL2017 conference delegates
News
Pulmatrix’s PUR1900 gets additional QIDP designation
Pulmatrix has announced that its PUR1900 itraconazole DPI has received Qualified Infectious Disease Product (QIDP) designation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. PUR1900 received Orphan Drug designation in 2016 and QIDP status in January 2017 for the treatment of ABPA in cystic fibrosis patients. In September … [Read more...] about Pulmatrix’s PUR1900 gets additional QIDP designation
Impel NeuroPharma appoints Jon Congleton as President and CEO
Intranasal drug developer Impel NeuroPharma has announced the appointment of former Nivalis Therapeutics leader Jon Congleton as the company’s new President and Chief Executive Officer (CEO). Congleton was most recently President and CEO of Nivalis and had previously served in a number of executive roles at Teva. He succeeds an interim CEO, co-Founder John Hoekman, … [Read more...] about Impel NeuroPharma appoints Jon Congleton as President and CEO
Recent advances in inhalation science will be featured at DDL 2017
The 700-plus OINDP specialists expected to convene at the Edinburgh International Conference Centre December 6-8 for this year's Drug Delivery to the Lungs (DDL) meeting will notice a few small changes designed to further the meeting's mission of encouraging inhalation research and to accommodate the growing numbers of delegates and exhibitors, organizers say. One … [Read more...] about Recent advances in inhalation science will be featured at DDL 2017
Synairgen considers developing its inhaled interferon beta for COPD
Synairgen has announced that it is considering development of its SNG001 inhaled interferon beta for the treatment of COPD. SNG001 was previously in development for the prevention of exacerbations caused by viral lung infections in asthma patients. In 2012, the company announced positive results from a Phase 2 study demonstrating that SNG001 produced statistically … [Read more...] about Synairgen considers developing its inhaled interferon beta for COPD
Micro-Sphere adds Harro Höfliger machine for additional DPI capsule filling capacity
CDMO Micro-Sphere has added a Harro Höfliger Modu-C MS capsule filling machine at its Lugano, Switzerland facility as part of a €19 million expansion, the company said, adding that the new machine offers 100% check weight control for accurate DPI capsule filling. Micro-Sphere Founder and President of the Board Michele Müller commented, “Low dose capsule filling is … [Read more...] about Micro-Sphere adds Harro Höfliger machine for additional DPI capsule filling capacity
Engage Therapeutics closes $23 million series A financing round to fund development of inhaled alprazolam
Engage Therapeutics has closed a $23 million Series A financing round led by TPG Biotech that will fund a Phase 2b clinical trial of an inhaled alprazolam for the treatment of acute epileptic seizures. Alexza Pharmaceuticals, which has developed the Staccato alprazolam through Phase 2a, registered the trademark for Engage Therapeutics in 2015. According to one … [Read more...] about Engage Therapeutics closes $23 million series A financing round to fund development of inhaled alprazolam
Frédéric Kahn joins Hovione as VP of Marketing and Sales
CDMO and device company Hovione has announced the appointment of Frédéric Kahn as VP Marketing and Sales. Kahn most recently served as VP Global Head of Key Account Management at Lonza and previously held executive positions at NextPharma and Gerresheimer. Hovione CEO Guy Villax commented, “We are delighted to welcome Mr. Kahn to Hovione. He is an excellent … [Read more...] about Frédéric Kahn joins Hovione as VP of Marketing and Sales
Savara initiates Phase 3 trial of AeroVanc for MRSA lung infections in CF patients
Savara has announced the initiation of a Phase 3 study of its AeroVanc vancomycin DPI for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infections in cystic fibrosis patients. The AVAIL study is expected to enroll about 200 patients who will receive either twice daily AeroVanc or an inhaled placebo in the first portion of the study over … [Read more...] about Savara initiates Phase 3 trial of AeroVanc for MRSA lung infections in CF patients
Ola Nerbrink joins Inhalation Sciences as Senior Sales Advisor
Former Medicon Valley Inhalation Consortium (MVIC) CEO Ola Nerbrink has joined PreciseInhale maker Inhalation Sciences (ISAB) as Senior Sales Advisor, the company said. Nerbrink, who stepped down as MVIC CEO earlier this year, founded Respiron Consulting in 2009 after having worked at AstraZeneca and Novo Nordisk. The PreciseInhale system generates dry powder … [Read more...] about Ola Nerbrink joins Inhalation Sciences as Senior Sales Advisor